At ASH 2019, they had the respect and benefit to introduce a front‑line investigation of acalabrutinib in patients with constant lymphocytic leukemia
Read MoreAt ASH 2019, they had the respect and benefit to introduce a front‑line investigation of acalabrutinib in patients with constant lymphocytic leukemia
Read More